FDA “outside activity”
This article was originally published in The Tan Sheet
Executive Summary
The agency "is taking several additional steps to protect against potential conflicts of interest" among employees that will go in to effect as soon as possible, FDA announces June 4. The measures include conducting an annual review of outside activities, expanding the number of FDA employees required to file declarations of their financial holdings and release of an agency-wide "Staff Manual Guide" on outside activities. FDA also announced the results of a review on all outside activities performed by agency employees, which Acting Commissioner Lester Crawford said did not identify any other activities of concern. The review covered more than 1,800 HHS form 520s entitled "request for approval of outside activity" for both paid and unpaid work by FDA employees. FDA announced revisions to its procedure for reviewing outside activities of agency employees on May 18, the same day a House Oversight & Investigations Subcommittee hearing addressed the ethics of outside consulting arrangements by NIH employees...
You may also be interested in...
OIG Report Finds “Inadequacies” In FDA Review Of Employee Activities
The "quality and extent" of information provided to FDA by employees seeking to participate in outside activities should be improved by requiring additional details on the nature of the activity, Inspector General Daniel Levinson recommends in a recent report
FDA Conflict Of Interest Policies Will Be Reviewed By House Committee
The House Energy & Commerce Committee will review FDA's conflict-of-interest procedures as part of an expanding probe that initially focused on NIH employee consulting arrangements
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.